OncoZenge AB (publ) (STO:ONCOZ)
Sweden
· Delayed Price · Currency is SEK 5.74
-0.61 (-9.61%)
At close: Mar 9, 2026
OncoZenge AB Company Description
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden.
It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity.
The company was incorporated in 2020 and is headquartered in Bromma, Sweden.
OncoZenge AB (publ)
| Country | Sweden |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Stian Kildal |
Contact Details
Address: GustavslundsvAegen 34 Bromma, 167 51 Sweden | |
| Phone | 46 8 31 14 20 |
| Website | oncozenge.com |
Stock Details
| Ticker Symbol | ONCOZ |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0015504097 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stian Kildal | Chief Executive Officer |
| Michael Owens B.A., B.S., B.S.B.A | Chief Financial Officer |
| Ida Sparrfeldt | Chief Auditor |
| Tuulikki Lindmark | Head of CMC in Phase 3 Sponsor Team |
| Dr. Marie-Louise Helena Fjallskog M.D., Ph.D. | Chief Medical Officer |